Regeneron Pharmaceuticals, Inc. (REGN)
After hours:
| Previous close | 690.88 |
| Open | 690.12 |
| Bid | 670.07 x 800 |
| Ask | 695.53 x 800 |
| Day's range | 682.90 - 697.01 |
| 52-week range | 492.13 - 747.42 |
| Volume | |
| Avg. volume | 646,066 |
| Market cap | 75.073B |
| Beta (5Y monthly) | 0.24 |
| PE ratio (TTM) | 9.72 |
| EPS (TTM) | 70.31 |
| Earnings date | 03 Aug 2022 - 08 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 703.14 |
- Motley Fool
Why Regeneron Investors Shouldn't Fear Its Patent Cliff
Biotechnology giant Regeneron's (NASDAQ: REGN) eye medication EYLEA is one of the best-selling blockbuster drugs around, generating $9.4 billion sales globally in 2021. The drug is approved for a number of eye diseases and has been a mainstay for Regeneron for the past decade. Although its patents are nearing the end of their lifespan, Regeneron has a number of new treatments that will step in to replace lost revenue.
- Zacks
SpringWorks (SWTX) Down Despite Desmoid Tumors Study Meeting Goal
SpringWorks' (SWTX) phase III study evaluating its investigational candidate, nirogacestat, in adult patients with progressing desmoid tumors, meets primary and key secondary endpoints.
- Zacks
Biotech Stock Roundup: ETTX Up on Acquisition Deal, REGN Offers Updates
Regulatory updates and acquisition news from Entasis (ETTX) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.
